AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21738622 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for four weeks
Number of subjects: 80
Study 21738622 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 80
Study 21738622 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram and age interaction
Number of subjects: 80
Study 19565883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones anti-tuberculosis drugs (3RFT AM Ofx Pto PAS‐INH/5RFT Ofx Pto PAS‐INH)
Number of subjects: 154
Study 19565883 — intervention group
Group type: COMPARATOR
Intervention: Re-treatment regimen (3 H3R3Z3E3S3/5 H3R3E3)
Number of subjects: 154
Study 16996612 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine eye drops once nightly for 2 years
Number of subjects: 400
Study 16996612 — intervention group
Group type: COMPARATOR
Intervention: Vehicle eye drops (placebo) once nightly for 2 years
Number of subjects: 400
Study 12507707 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (50-500 microg kg(‐1) x min(‐1))
Number of subjects: 62
Study 12507707 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion (0.05-0.5 microg kg(‐1) x min(‐1))
Number of subjects: 62
Study 10958215 — intervention group
Group type: EXPERIMENTAL
Intervention: Open antireflux surgery
Number of subjects: 310
Study 10958215 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole therapy (40 or 60 mg)
Number of subjects: 310
Study 8942328 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 100 micrograms
Number of subjects: 45
Study 8942328 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 micrograms
Number of subjects: 45
Study 8942328 — intervention group
Group type: COMPARATOR
Intervention: Control (0.0625% bupivacaine + sufentanil 10 micrograms)
Number of subjects: 45
Study 8942328 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study 8942328 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (all doses)
Number of subjects: 45
Study 1955716 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 33
Study 1955716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 6138072 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 30
Study 6138072 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesparax (150 mg secobarbital, 50 mg brallobarbital, 50 mg hydroxyzine)
Number of subjects: 30
Study 31618540 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy (pravastatin)
Number of subjects: 214
Study 28739318 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard yearly intervention with fluoride varnish applied biannually
Number of subjects: 801
Study 28739318 — intervention group
Group type: COMPARATOR
Intervention: Standard yearly intervention
Number of subjects: 801
Study 25427656 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered nurse‐led care management intervention
Number of subjects: 1120
Study 25427656 — intervention group
Group type: EXPERIMENTAL
Intervention: Program participants (n = 251)
Number of subjects: 1120
Study 25427656 — intervention group
Group type: COMPARATOR
Intervention: Control group (propensity score‐matched controls, n = 251)
Number of subjects: 1120
Study 23438935 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250 mg bid
Number of subjects: 44
Study 23438935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20803023 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus plantarum HEAL 9 and Lactobacillus paracasei 8700:2)
Number of subjects: 272
Study 20803023 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 272
Study 19439594 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (systemically administered)
Number of subjects: 0
Study 19439594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (systemically administered)
Number of subjects: 0
Study 16761831 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES) at 12 cycles/min for one week
Number of subjects: 11
Study 16761831 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric electrical stimulation (GES) continued after one week
Number of subjects: 11
Study 16761831 — intervention group
Group type: COMPARATOR
Intervention: No stimulation after trial period
Number of subjects: 11
Study 15277331 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 to 100 mg/d
Number of subjects: 219
Study 15277331 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 to 100 mg/d
Number of subjects: 219
Study 15277331 — intervention group
Group type: COMPARATOR
Intervention: Losartan vs Atenolol
Number of subjects: 219
Study 11716168 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg m(‐3) H2SO4
Number of subjects: 13
Study 11716168 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 microg m(‐3) H2SO4
Number of subjects: 13
Study 11716168 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 13
Study 9155945 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine at 250 mg/day for 12 weeks
Number of subjects: 118
Study 9155945 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 118
Study 8301727 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein patch (VP) closure
Number of subjects: 136
Study 8301727 — intervention group
Group type: EXPERIMENTAL
Intervention: Obligatory vein patch (OVP) closure
Number of subjects: 136
Study 8301727 — intervention group
Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 136
Study 8301727 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 136
Study 3291646 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol, 2 mg/kg-propofol infusion, 1-20 mg/min-nitrous oxide, 60-70%
Number of subjects: 120
Study 3291646 — intervention group
Group type: COMPARATOR
Intervention: Thiopental, 4 mg/kg-isoflurane, 0.2-3%-nitrous oxide, 60-70% (control)
Number of subjects: 120
Study 31955381 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral for post-discharge medication use review
Number of subjects: 59
Study 31955381 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge care
Number of subjects: 59
Study 28645953 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training with a practical test including feedback (T)
Number of subjects: 587
Study 28645953 — intervention group
Group type: COMPARATOR
Intervention: CPR training only (O)
Number of subjects: 587
Study 28645953 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR training with reflection and a practical test including feedback (RT)
Number of subjects: 587
Study 28645953 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 587
Study 25352617 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-week, twice weekly, 90-minute exercise and education programme
Number of subjects: 55
Study 25352617 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 55
Study 23415171 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAS patients with CHF
Number of subjects: 30
Study 23415171 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAS patients with CHF (after 100% oxygen administration)
Number of subjects: 30
Study 23415171 — intervention group
Group type: COMPARATOR
Intervention: Control CHF patients (room air and 100% oxygen)
Number of subjects: 30
Study 21496654 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 800 mg ibuprofen and 1000 mg acetaminophen
Number of subjects: 100
Study 21496654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18071191 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-microg misoprostol vaginal insert
Number of subjects: 12
Study 18071191 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-microg misoprostol vaginal insert
Number of subjects: 12
Study 18071191 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-microg misoprostol vaginal insert
Number of subjects: 12
Study 18071191 — intervention group
Group type: COMPARATOR
Intervention: 200-microg oral misoprostol
Number of subjects: 12
Study 16948481 — intervention group
Group type: EXPERIMENTAL
Intervention: Three accumulated sessions (3 x 167 kcal)
Number of subjects: 9
Study 16948481 — intervention group
Group type: COMPARATOR
Intervention: One continuous session (1 x 500 kcal)
Number of subjects: 9
Study 16948481 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (continuous and accumulated)
Number of subjects: 9
Study 12541116 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 ml 50% Gastrografin
Number of subjects: 23
Study 12541116 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ml 50% Gastrografin
Number of subjects: 23
Study 12541116 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 23
Study 10628714 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nose
Number of subjects: 19
Study 9178481 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 micrograms liquid PRP-OMPC vaccine
Number of subjects: 908
Study 9178481 — intervention group
Group type: COMPARATOR
Intervention: 15.0 micrograms lyophilized PRP-OMPC vaccine
Number of subjects: 908
Study 1489129 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized beclomethasone (5 puffs four times a day for 6 weeks)
Number of subjects: 30
Study 1489129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3516262 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU i.v. weekly for 12 months
Number of subjects: 0
Study 3516262 — intervention group
Group type: COMPARATOR
Intervention: CMF i.v. every 2 weeks for 12 months
Number of subjects: 0
Study 3516262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy after relapse (commonly with CMFVP or CMF)
Number of subjects: 0
Study 3516262 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy or radiation therapy as initial therapy after relapse
Number of subjects: 0
Study 3516262 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight increase greater than 10 kg during adjuvant chemotherapy
Number of subjects: 0
Study 3516262 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly observation during treatment
Number of subjects: 0
Study 31586194 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive psychology (PP) based intervention to promote physical activity
Number of subjects: 255
Study 29286595 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg/d) plus standard methadone maintenance treatment (TAU)
Number of subjects: 120
Study 29286595 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized CBT plus standard methadone treatment (TAU)
Number of subjects: 120
Study 29286595 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine plus computerized CBT plus TAU
Number of subjects: 120
Study 29286595 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus TAU
Number of subjects: 120
Study 26987347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3883
Study 26987347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3883
Study 24052094 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) at 1.5 ATA
Number of subjects: 60
Study 24052094 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) at 2.0 ATA
Number of subjects: 60
Study 24052094 — intervention group
Group type: COMPARATOR
Intervention: Sham compression
Number of subjects: 60
Study 22930115 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg loading dose / 10 mg maintenance dose
Number of subjects: 93
Study 22930115 — intervention group
Group type: COMPARATOR
Intervention: High dose clopidogrel 150 mg maintenance dose
Number of subjects: 93
Study 20379680 — intervention group
Group type: EXPERIMENTAL
Intervention: G2: composite, soft‐start technique
Number of subjects: 32
Study 20379680 — intervention group
Group type: COMPARATOR
Intervention: G1: composite, conventional light curing technique (control)
Number of subjects: 32
Study 20379680 — intervention group
Group type: EXPERIMENTAL
Intervention: G3: amalgam/composite association (amalcomp)
Number of subjects: 32
Study 20379680 — intervention group
Group type: EXPERIMENTAL
Intervention: G4: resin‐modified glass ionomer cement/composite, open sandwich technique
Number of subjects: 32
Study 17682365 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke education program
Number of subjects: 547
Study 17682365 — intervention group
Group type: COMPARATOR
Intervention: Standard health class
Number of subjects: 547
Study 16227416 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone premedication
Number of subjects: 355
Study 16227416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 16227416 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 355
Study 12432337 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (MP) 100 mg transvaginally 12 days/month
Number of subjects: 60
Study 12432337 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) 10 mg p.o. 12 days/month
Number of subjects: 60
Study 12432337 — intervention group
Group type: COMPARATOR
Intervention: Transdermic nor-ethisterone acetate (NETA) 0.25 mg integrated in the ethinil-estradiol patches for the last two weeks of each cycle
Number of subjects: 60
Study 10628599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure limited ventilation (peak inflation pressure ≤30 cm H2O, tidal volume ≤8 mL/kg)
Number of subjects: 28
Study 10628599 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (peak inflation pressure ≤50 cm H2O, tidal volume 10-15 mL/kg)
Number of subjects: 28
Study 10628599 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure limited ventilation
Number of subjects: 28
Study 10628599 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 28
Study 8533625 — intervention group
Group type: EXPERIMENTAL
Intervention: DSG/EE
Number of subjects: 20
Study 8533625 — intervention group
Group type: COMPARATOR
Intervention: LNG/EE
Number of subjects: 20
Study 2193377 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 60
Study 2193377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 329712 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital (50 or 150 mg) or sodium secobarbital (50 or 150 mg) or placebo
Number of subjects: 509
Study 329712 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (5, 10 or 15 mg) or hydroxyzine (50, 100, or 150 mg) or placebo
Number of subjects: 509
Study 329712 — intervention group
Group type: COMPARATOR
Intervention: Morphine (5 or 10 mg) or meperidine (50 or 100 mg) or placebo
Number of subjects: 509
Study 31260793 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 10 mg
Number of subjects: 2400
Study 31260793 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 25 mg
Number of subjects: 2400
Study 31260793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400
Study 31260793 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 2400
Study 27757803 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 131I (1.1 GBq)
Number of subjects: 140
Study 27757803 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose 131I (3.7 GBq)
Number of subjects: 140
Study 27757803 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 140
Study 25597383 — intervention group
Group type: EXPERIMENTAL
Intervention: sertindole
Number of subjects: 0
Study 25597383 — intervention group
Group type: COMPARATOR
Intervention: clozapine
Number of subjects: 0
Study 25597383 — intervention group
Group type: COMPARATOR
Intervention: olanzapine
Number of subjects: 0
Study 25597383 — intervention group
Group type: COMPARATOR
Intervention: quetiapine
Number of subjects: 0
Study 25597383 — intervention group
Group type: COMPARATOR
Intervention: FGAs
Number of subjects: 0
Study 25597383 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 0
Study 23637733 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 µg H1N1pnd09 antigen with MF59‐adjuvant (Pa7.5 µg)
Number of subjects: 207
Study 21320303 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reminiscence-based education programme for care staff
Number of subjects: 306
Study 21320303 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 306
Study 18790032 — intervention group
Group type: EXPERIMENTAL
Intervention: FLZ microemulsion based gel (FLZ-MBG)
Number of subjects: 0
Study 18790032 — intervention group
Group type: COMPARATOR
Intervention: Candid V gel (marketed clotrimazole gel)
Number of subjects: 0
Study 17760633 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial rectus muscle re-recession (n = 12)
Number of subjects: 25
Study 17760633 — intervention group
Group type: COMPARATOR
Intervention: Lateral rectus muscle resection (n = 13)
Number of subjects: 25
Study 15588296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia group (n=14)
Number of subjects: 30
Study 15588296 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low back pain group (n=10)
Number of subjects: 30
Study 15588296 — intervention group
Group type: COMPARATOR
Intervention: Normal control group (n=6)
Number of subjects: 30
Study 11477202 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone therapy
Number of subjects: 40
Study 9752139 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led shared care
Number of subjects: 0
Study 7978176 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.036 mg/kg body weight
Number of subjects: 52
Study 7978176 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous recovery
Number of subjects: 52
Study 7978176 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine administration timing
Number of subjects: 52
Study 7978176 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-reversal time
Number of subjects: 52
Study 7978176 — intervention group
Group type: EXPERIMENTAL
Intervention: PTC monitoring
Number of subjects: 52
Study 3398555 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dipyridamole (19 patients)
Number of subjects: 58
Study 3398555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole (21 patients)
Number of subjects: 58
Study 3398555 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 patients)
Number of subjects: 58
Study 3398555 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and intravenous dipyridamole
Number of subjects: 58
Study 31985914 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% lotion
Number of subjects: 1614
Study 31985914 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1614
Study 29486041 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem-vaborbactam (2g/2g over 3 hours; n=274)
Number of subjects: 550
Study 29486041 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam (4g/0.5g over 30 minutes; n=276)
Number of subjects: 550
Study 29486041 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem-vaborbactam
Number of subjects: 550
Study 29486041 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 550
Study 26658907 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alteplase
Number of subjects: 0
Study 26658907 — intervention group
Group type: COMPARATOR
Intervention: Presence of HAS
Number of subjects: 0
Study 26658907 — intervention group
Group type: COMPARATOR
Intervention: More extensive HAS
Number of subjects: 0
Study 26658907 — intervention group
Group type: COMPARATOR
Intervention: Increasing age
Number of subjects: 0
Study 26658907 — intervention group
Group type: COMPARATOR
Intervention: Proximal vs distal HAS
Number of subjects: 0
Study 26658907 — intervention group
Group type: COMPARATOR
Intervention: More vs less extensive HAS
Number of subjects: 0
Study 26658907 — intervention group
Group type: COMPARATOR
Intervention: Presence vs absence of HAS
Number of subjects: 0
Study 26303505 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Strength Training (EST) program with motivationally-tailored behavioral counselling
Number of subjects: 318
Study 26303505 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Strength Training (EST) program
Number of subjects: 318
Study 26303505 — intervention group
Group type: COMPARATOR
Intervention: Standard Strength Training (SST) program
Number of subjects: 318
Study 23593327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg orally thrice daily for 8 weeks
Number of subjects: 26
Study 23593327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 20621562 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue antihypertensive drugs
Number of subjects: 763
Study 20621562 — intervention group
Group type: COMPARATOR
Intervention: Stop antihypertensive drugs
Number of subjects: 763
Study 18855822 — intervention group
Group type: EXPERIMENTAL
Intervention: counseling + methadone
Number of subjects: 211
Study 18855822 — intervention group
Group type: COMPARATOR
Intervention: counseling only
Number of subjects: 211
Study 18855822 — intervention group
Group type: COMPARATOR
Intervention: counseling + transfer
Number of subjects: 211
Study 15837248 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting TAXUS stent
Number of subjects: 1314
Study 15837248 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal equivalent stent
Number of subjects: 1314
Study 12067045 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (not specified in detail)
Number of subjects: 3084
Study 10502591 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization
Number of subjects: 192
Study 10502591 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 192
Study 8904857 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchodilator therapy (albuterol or ipratropium bromide)
Number of subjects: 8
Study 1872596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose tablets)
Number of subjects: 60
Study 1872596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 60